RET Gene Rearrangements by FISH
Rearrangement of the RET gene, also known as RET/PTC rearrangement, is the most common genetic alteration identified in papillary thyroid carcinomas. It is formed by fusion of the tyrosine kinase domain of RET to genes located on different chromosomes. The genes fused with RET are constitutively expressed in thyroid follicular cells and drive the expression of the chimeric RET/PTC oncogene. RET/PTC gene fusion is detected in 5-40% of papillary thyroid carcinoma and found rarely in other types of thyroid lesions.
There are at least13 different types of RET/PTC rearrangements among which RET/PTC1 and RET/PTC3 are most frequent ones. RET/PTC1 is formed by fusion with the CCDC6 or H4 gene, and RET/PTC3 by fusion with the ELE1 gene. RET/PTC1 appears to be the most common rearrangement in spontaneous adult and childhood thyroid cancers, whereas both RET/PTC1 and RET/PTC3 rearrangements are observed with a high prevalence in radiation-induced thyroid cancers. Other variant rearrangements have been isolated just in rare cases.
Recent studies have documented the presence of RET/PTC mutations in Hashimoto’s thyroiditis, benign adenomas, hyperplastic nodules, Hurthle cell carcinoma, and in hyalinizing trabecular tumors of the thyroid. The presence or higher expression of a RET fusion protein has been linked to regional invasion and lymph node metastasis. Finally, RET rearrangements may be very useful in the evaluation of thyroid nodules with undefined cytology/histology.
- Aid in the diagnosis of papillary thyroid carcinoma
- Confirmatory test for papillary thyroid carcinoma when the conventional cytology yields inconclusive results
- Therapy selection and disease management
Negative:
- RET/PTC rearrangement not detected. No disruption of RET gene either due to ionizing radiation or reactive oxygen species and fusion with heterologous genes.
Positive:
- RET/PTC rearrangement detected. Fusion of the tyrosine kinase domain of RET to heterologous genes located on different chromosomes.
Negative for RET/PTC gene fusion. No disruption of RET gene and fusion with heterologous genes
Formalin-fixed paraffin embedded (FFPE) tissue block, fine needle aspiration (FNA), frozen tissue.
Stability
FFPE samples are stable at room temperature for longer.
- Front Endocrinol (Lausanne). 2012;3:54. [PMID: 22654872]
- Endocr Pathol. 2002;13:3-16. Review. [PMID: 12114746]
- Oncogene. 1994;9: 509-5016. [PMID: 8290261]
- Pathol Oncol Res. 2018 Nov 22. doi: 10.1007/s12253-018-0540-3. [PMID: 30467698]
- Cancer Genet. 2019;238:10-17. [PMID: 31425920]
- Cancer Res. 2008;68:7176-7182. [PMID: 18757433]
- J Clin Endocrinol Metab. 2006;91:3603-3610. [PMID: 16772343]
- J Clin Endocrinol Metab. 2004;89:2281-9. [PMID: 15126554]
- Mol Endocrinol. 2003;17:1382-1394. [PMID: 12738763]
- Endocr Pathol. 2002;13:3-16. Review. [PMID: 12114746]
- Oncogene. 1994;9: 509-5016. [PMID: 8290261]